MLP AG / Key word(s): Finance
11.11.2010 07:33
---------------------------------------------------------------------------
MLP maintains positive trend with growth in revenues and earnings
- Q3: Total revenues increase to EUR 116.0 million, EBIT rises to EUR 8.7
million
- 9M: Significan ...
As a result of higher production DNO International ASA delivered increased
revenues and improved results from operations in the third quarter.
"I am pleased to note that the good trend in our financial results and cash flow
from operations continued into the third quarter. DNO will now ente ...
4SC AG / Key word(s): Quarter Results
11.11.2010 07:30
---------------------------------------------------------------------------
Planegg-Martinsried, 11 November 2010 - 4SC (Frankfurt, Prime Standard:
VSC), a drug discovery and development company focused on autoimmune and
cancer indications, t ...
Continuous Improvements in Margins and Further Backlog Growth
Bergen, Norway, November 11, 2010. Vizrt Ltd. (Oslo Main List: VIZ)
For the first nine months of 2010, the Company recorded a 24% growth in revenues
as compared to 2009, with BG the strongest contributor to revenue growth.
&nb ...
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery
company, publishes its business update for the third quarter of 2010.
Highlights
Proprietary drug delivery technologies
OctoPlus offers a platform of controlled release drug delivery technologies ...
Heijmans reports higher profits by lower revenues
· Operating profit margin of almost 2% in the third quarter of
2010,compared to1% in the same period of last year;
· & ...
STADA Arzneimittel AG / Key word(s): Interim Report
11.11.2010 07:25
---------------------------------------------------------------------------
Important items at a glance
- Group sales EUR 1,177.8 million (+3%)
- Adjusted EBITDA EUR 224.2 million (+12%)
- Adjusted earnings per share EU ...
11 November 2010, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC:
ATSMY) announces that a scheduled interim analysis showed that the ATTRACT-2
trial should stop as ASA404 was unlikely to provide any benefit as a second-line
treatment for non-small cell lung cancer.
Glyn Edwards, CE ...
Novartis International AG /
Novartis discontinues ASA404 clinical trial program and shifts focus to other
cancer compounds in early and late stage development
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
* Interim results ...
Oslo, Norway, 11 November 2010
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug discovery and
development company, and Clovis Oncology, Inc., announced today a new agreement
for the further development and commercialisation of CP-4126 (also known as CO-
101), which is curren ...
Wilh. Wilhelmsen Holding ASA (WWH) continues to record a year on year increase
in operating profit. The shipping segment is the main contributor to the solid
improvement.
Total operating profit amounted to USD 74.3 million for the third quarter of
2010, up from USD 47.8 million for the ...
* Net asset value per share on 30 September 2010 amounted to EUR 11.42 (EUR
9.15). The total net asset value amounted to EUR 398m (EUR 325m),
corresponding to an increase of 3.8% (11.2%) during the third quarter (q-on-
q) and an increase of 16.6% (22.5%) since year end. Since 3 ...
Celesio AG / Key word(s): Quarter Results
11.11.2010 07:00
---------------------------------------------------------------------------
Celesio confirms forecast following successful third quarter
Group EBITDA up on previous year
Medco Celesio joint venture launched and expansion of DocMorris ...
* New deal expands existing relationship to include global rights to CP-4126
* Clavis Pharma to receive up to $205 million in additional staged payments,
including a $10 million signing fee, and tiered double-digit royalties on
sales
Oslo, Norway, and Boulder, CO, USA. No ...
Click here for the press release
Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), Europe's
leading adult stem cell storage bank, announces its trading update for the
quarter ended 30 September 2010.
Highlights for the period were:
* Third quarter revenue of ?9.6 million ( ...
(Oslo 11 November 2010) Director for strategy and business development in
ErgoGroup, Jakob van der Hagen, has acquired 4.000 shares in EDB ErgoGroup. The
shares are acquired at NOK 16,40. Van der Hagen has after the transaction 4.000
shares in EDB ErgoGroup.
This information is s ...
Tagesgeld-Konditionen
Pressemitteilungen der Druckerei WIRmachenDRUCK finden Sie auf wir-machen-druck.de unter Aktuelles.
Hochwertiges und günstiges Spielzeug, sowie Bastelbedarf und Bastelmaterial gibt es im didagoshop.
Moderne Badmöbel und viele tolle Möbel für Ihr Zuhause.
Für ein effektives und erfolgreiches Direktmarketing. Adressen kaufen bei Best Adress.
Mit einem einfachen Strompreisvergleich können Sie jeden Monat sparen.
Günstige Kredite für Selbstständige und Freiberufler - auch in schwierigen Fällen!
Kfz Ersatzteile von 100Pro-Ersatzteile.de, Autoteile in Erstausrüsterqualität.